Neimeth International Pharmaceuticals Plc (NGX:NEIMETH)
2.490
-0.260 (-9.45%)
At close: Mar 14, 2025
NGX:NEIMETH Balance Sheet
Financials in millions NGN. Fiscal year is January - December.
Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2022 | FY 2021 | 2020 - 2016 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | 2020 - 2016 |
Cash & Equivalents | 1,907 | 2,253 | 448.37 | 810.49 | 2,025 | Upgrade
|
Cash & Short-Term Investments | 1,907 | 2,253 | 448.37 | 810.49 | 2,025 | Upgrade
|
Cash Growth | -15.35% | 402.45% | -44.68% | -59.98% | -23.14% | Upgrade
|
Accounts Receivable | 1,259 | 757.72 | 1,299 | 1,209 | 1,211 | Upgrade
|
Other Receivables | 329.99 | - | - | - | - | Upgrade
|
Receivables | 1,606 | 803.82 | 1,355 | 1,264 | 1,244 | Upgrade
|
Inventory | 2,036 | 2,065 | 1,719 | 1,732 | 1,464 | Upgrade
|
Prepaid Expenses | 50.61 | 40.6 | 21.46 | 103.93 | 18.58 | Upgrade
|
Other Current Assets | 47.77 | 74.64 | 77.99 | 41.39 | 75.36 | Upgrade
|
Total Current Assets | 5,648 | 5,237 | 3,622 | 3,951 | 4,828 | Upgrade
|
Property, Plant & Equipment | 4,238 | 3,665 | 2,855 | 2,436 | 1,412 | Upgrade
|
Other Long-Term Assets | 32.25 | 33.14 | 34.01 | 34.23 | 35.1 | Upgrade
|
Total Assets | 9,918 | 8,935 | 6,512 | 6,422 | 6,275 | Upgrade
|
Accounts Payable | 139.51 | 117.5 | 113.09 | 94.65 | 140.32 | Upgrade
|
Accrued Expenses | 4,069 | 2,197 | 998.55 | 762.98 | 502.24 | Upgrade
|
Short-Term Debt | - | - | - | 913.16 | 13.57 | Upgrade
|
Current Portion of Long-Term Debt | 4,747 | 3,883 | 2,158 | 1,096 | 1,100 | Upgrade
|
Current Portion of Leases | 28.79 | 40.64 | - | - | - | Upgrade
|
Current Income Taxes Payable | 56.33 | 68.82 | 86.77 | 103.92 | 135.73 | Upgrade
|
Current Unearned Revenue | 406.71 | 406.71 | 119.04 | 76.93 | 76.93 | Upgrade
|
Other Current Liabilities | 190.36 | 255.2 | 154.51 | 149.7 | 150.96 | Upgrade
|
Total Current Liabilities | 9,638 | 6,969 | 3,630 | 3,198 | 2,119 | Upgrade
|
Long-Term Debt | 301.2 | 288.18 | 1,487 | 1,322 | 1,933 | Upgrade
|
Long-Term Unearned Revenue | 102.51 | 102.51 | 509.21 | 702.17 | 702.17 | Upgrade
|
Long-Term Deferred Tax Liabilities | 106.23 | 106.23 | 106.23 | 106.23 | 106.23 | Upgrade
|
Other Long-Term Liabilities | -0 | - | - | - | - | Upgrade
|
Total Liabilities | 10,148 | 7,466 | 5,733 | 5,328 | 4,861 | Upgrade
|
Common Stock | 2,137 | 2,137 | 949.58 | 949.58 | 949.58 | Upgrade
|
Additional Paid-In Capital | 2,378 | 2,378 | 8.82 | 27.38 | 104.88 | Upgrade
|
Retained Earnings | -4,744 | -3,045 | -179.63 | 117 | 359.61 | Upgrade
|
Shareholders' Equity | -229.94 | 1,469 | 778.77 | 1,094 | 1,414 | Upgrade
|
Total Liabilities & Equity | 9,918 | 8,935 | 6,512 | 6,422 | 6,275 | Upgrade
|
Total Debt | 5,077 | 4,212 | 3,645 | 3,331 | 3,046 | Upgrade
|
Net Cash (Debt) | -3,170 | -1,959 | -3,197 | -2,521 | -1,021 | Upgrade
|
Net Cash Per Share | -0.74 | -0.46 | -1.68 | -1.33 | -0.54 | Upgrade
|
Filing Date Shares Outstanding | 4,276 | 4,273 | 1,899 | 1,899 | 1,899 | Upgrade
|
Total Common Shares Outstanding | 4,276 | 4,273 | 1,899 | 1,899 | 1,899 | Upgrade
|
Working Capital | -3,990 | -1,732 | -7.53 | 753.78 | 2,708 | Upgrade
|
Book Value Per Share | -0.05 | 0.34 | 0.41 | 0.58 | 0.74 | Upgrade
|
Tangible Book Value | -229.94 | 1,469 | 778.77 | 1,094 | 1,414 | Upgrade
|
Tangible Book Value Per Share | -0.05 | 0.34 | 0.41 | 0.58 | 0.74 | Upgrade
|
Land | 85.87 | 85.87 | 85.87 | 85.87 | 85.87 | Upgrade
|
Buildings | 253.44 | 183.63 | 165.75 | 163.68 | 132.24 | Upgrade
|
Machinery | 1,875 | 1,804 | 1,930 | 1,833 | 1,481 | Upgrade
|
Construction In Progress | 3,468 | 2,966 | 1,883 | 1,538 | 778.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.